Reuters logo
BRIEF-Health Canada grants priority review status to trifluridine and tipiracil for refractory metastatic colorectal cancer
October 20, 2017 / 11:09 AM / a month ago

BRIEF-Health Canada grants priority review status to trifluridine and tipiracil for refractory metastatic colorectal cancer

Oct 20 (Reuters) - Otsuka Holdings Co Ltd

* Taiho Pharma Canada - Health Canada accepted for review new drug submission for trifluridine, tipiracil,NDS granted priority review status​

* Taiho Pharma Canada - Health Canada’s review of NDS under priority review is expected to be completed in early 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below